First Participant Dosed in Pioneering Phase 1 Study of GZC8072, a Novel Weekly Oral Therapy #China #Beijing #GLP-1_RA #GZC8072 #GanLee_Pharmaceuticals
@newsen.bsky.socialExplore
@newsen.bsky.social
@newsen.bsky.socialFirst Participant Dosed in Pioneering Phase 1 Study of GZC8072, a Novel Weekly Oral Therapy #China #Beijing #GLP-1_RA #GZC8072 #GanLee_Pharmaceuticals